Celldex Therapeutics (CLDX) Shares Slide -2.53%

Celldex Therapeutics (CLDX) has risen sharply, recording gains of 0.65% in the past 4 weeks. However, the stock has corrected -2.53% in the past 1 week, providing a good buying opportunity on dips. Celldex Therapeutics (CLDX) : During the past 4 weeks, traders have been relatively bearish on Celldex Therapeutics (CLDX), hence the stock is down -2.62% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.47% relative to the S&P 500.

The stock has recorded a 20-day Moving Average of 0% and the 50-Day Moving Average is 3.56%. Celldex Therapeutics, Inc. is up 15.5% in the last 3-month period. Year-to-Date the stock performance stands at -70.54%.


Celldex Therapeutics (NASDAQ:CLDX): On Fridays trading session , Opening price of the stock was $4.69 with an intraday high of $4.69. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $4.58. However, the stock managed to close at $4.62, a loss of 2.12% for the day. On the previous day, the stock had closed at $4.72. The total traded volume of the day was 1,266,158 shares.

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.